Tech Company Financing Transactions
Emmecell Funding Round
Emmecell, operating out of Menlo Park, secured investment capital from Bausch & Lomb.
Transaction Overview
Company Name
Announced On
6/17/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support the continued advancement of Emmecell's clinical programs, expansion of operational capabilities, and development of its proprietary magnetic cell delivery platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3475 Edison Way T
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Emmecell is a clinical-stage biotechnology company developing cell-based therapies for eye diseases using its proprietary Magnetic Cell Delivery (MCD) nanoparticle platform. Headquartered in Menlo Park, California, the company focuses on minimally invasive, regenerative alternatives to traditional surgeries for conditions like corneal edema and macular degeneration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jeffrey Goldberg
Chief Executive Officer
Ramin Valian
Chief Operating Officer
Noelia Kunzevitzky
Co-Founder
Roger Goldberg
Browse more venture capital transactions:
Prev: 6/17/2026: Triveni Bio venture capital transaction
Next: 6/17/2026: Sonire Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document tech company VC transactions. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs